Rafael Amado Sells 2,739 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Rafael Amado sold 2,739 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $20.45, for a total transaction of $56,012.55. Following the transaction, the insider directly owned 57,022 shares in the company, valued at approximately $1,166,099.90. The trade was a 4.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Rafael Amado also recently made the following trade(s):

• On Thursday, April 2nd, Rafael Amado sold 9,910 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total transaction of $202,064.90.
• On Friday, March 13th, Rafael Amado sold 2,957 shares of Zai Lab stock. The shares were sold at an average price of $18.63, for a total transaction of $55,088.91.

Zai Lab Trading Down 3.0%

Shares of ZLAB stock opened at $20.74 on Friday. The company’s 50-day moving average price is $18.96 and its 200-day moving average price is $21.50. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -12.88 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a twelve month low of $15.96 and a twelve month high of $44.34.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share (EPS) for the quarter. The company had revenue of $127.60 million during the quarter. Zai Lab had a negative net margin of 38.15% and a negative return on equity of 22.81%. As a group, equities research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ZLAB. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st. Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. JPMorgan Chase & Co. reduced their price objective on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. UBS Group began coverage on shares of Zai Lab in a report on Wednesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Zacks Research lowered shares of Zai Lab from a “hold” rating to a “strong sell” rating in a report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

Institutional Trading of Zai Lab

An institutional investor recently bought a new position in Zai Lab stock. SG Americas Securities LLC purchased a new position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,754 shares of the company’s stock, valued at approximately $331,000. 41.65% of the stock is owned by institutional investors.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.